Trial Profile

A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Elotuzumab (Primary) ; FT 538 (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia; Multiple myeloma
Focus Adverse reactions; First in man
Sponsors Fate Therapeutics

19 Sep 2023 Status changed from active, no longer recruiting to discontinued because it was terminated by the sponsor.
28 Apr 2023 Status changed from recruiting to active, no longer recruiting.
13 Dec 2022 Results (n=6; data cutoff date: 5 Jul 2022) reporting safety data presented at the 64th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com